Clinical trial
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic…
NCT00326885 · Neovii Biotech, Industry · Completed
Key facts
| NCT number | NCT00326885 |
|---|---|
| Title | Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites |
| Official title | A Single-Arm, Open-Label, Phase II Study to Assess the Safety and Efficacy of the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) Administered Intraperitoneally in Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites |
| Lead sponsor | Neovii Biotech, Industry |
| Collaborators | Fresenius Biotech North America Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Ascites |
| Intervention type | Drug |
| Interventions | catumaxomab |
| Enrollment | 32 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Aug 1, 2010 |
| First posted | May 17, 2006 |
| Last update posted | Oct 17, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: